Delegates to the MIP European Life Sciences Forum 2017 included representatives from:AbzenaAstraZenecaAvidity IPAwapatentBialBristowsBTG InternationalCancer Research TechnologyCircassiaDechertDiamond BioPharmEuropean Medicines AgencyEUSA PharmaFinnegan Henderson Farabow Garrett & DunnerGilead SciencesGlenmark PharmaceuticalsGowling WLGGSKGW PharmaceuticalsJ A KempJuniper PharmaceuticalsKymabMars PetcareMcKesson Global Procurement & SourcingMédecins Sans FrontièresMedImmuneMereo Biopharma GroupMRC TechnologyMylanNovartisOxford BioTherapeuticsOxford Nanopore TechnologiesPowell GilbertPure IdeasRentsch PartnerShearn Delamore & CoTeva EuropeVega Software House
Federal Circuit’s Brunetti ruling: barring immoral or scandalous marks is unconstitutional restriction of free spee… https://t.co/MivCKFINHg
Federal Circuit rules in Amgen v Sandoz on remand from SCOTUS https://t.co/uYIkfVhCHG https://t.co/2OZAscsz32
RT @mdloney: Canada moves closer to joining the Hague Agreement with the release of proposed new Industrial Design Regulations https://t.co…
End of Year 2017
Tribal sovereign immunity: Taking a wrecking ball to the IPR system
The lawyer behind Allergan’s controversial transfer of patents to a Native American tribe says others are “lining up to do deals”. But, Michael Loney asks, will the PTAB rule that sovereign immunity applies in these types of deals?
The material on this site is for financial institutions, professional investors
and their professional advisers. It is for information only. Please read our
Terms and Conditions
before using the site. All material subject to strictly enforced copyright laws.
© 2017 Euromoney Institutional Investor PLC. For help please
see our FAQ.
Switching to MIP International